B2B Forecasting & Commercial Insight
Your sales, enquiry, quotation and pipeline data may already contain useful signals about what happens next.
Xenon Insight helps B2B firms identify those signals, test whether they are reliable and turn the findings into practical revenue forecasts and better commercial decisions.
25 years' senior B2B commercial experience | MBA with merit | Evidence-led analysis
Many B2B businesses forecast using the current order book, pipeline value and management judgement.
Those inputs matter, but they rarely provide the whole picture.
Useful signals may also sit within
The challenge is identifying which signals are meaningful and which are simply noise.
01
Assess the structure, completeness and commercial relevance of the available data.
02
Separate customers, products, sectors, teams or opportunity types where behaviour differs.
03
Examine trends, relationships, leading indicators and forecast assumptions.
04
Translate the findings into practical forecasts, management commentary and recommended actions.
The objective is not to replace commercial judgement. It is to make that judgement better informed.
Applied experience
More than three years of enquiry and turnover data were segmented and tested to determine whether current commercial activity could provide an earlier indication of following-month revenue.
Within a selected business stream, the initial analysis identified a Pearson correlation of approximately 0.70 between enquiry activity and following-month turnover.
The relationship was not used as a standalone forecast. It was combined with opening order book, current order intake, known opportunities and management judgement to support low, central and high forecast ranges.
The relationship was specific to the business stream, period and data analysed and should not be assumed to apply universally.
Pearson’s r ≈ 0.70
Clear positive relationship identified in the initial analysis.
Start here — Founding 10 offer
£495 one-off
A focused assessment of how predictable your revenue currently is and whether useful forward-looking signals exist within your commercial data.
Best for:Businesses that want a low-risk first assessment before committing to deeper analysis.
£1,500 one-off
A deeper diagnostic of sales, enquiry or pipeline performance, including segmentation, trend analysis and assessment of potential forecasting signals.
Best for:Businesses that need a clearer understanding of what is driving commercial performance.
£3,500 one-off
Detailed commercial analysis combined with a practical revenue forecast model, historical backtesting and management recommendations.
Best for:Businesses seeking stronger forecasting capability and a more robust evidence base for planning.
£750 per month
A recurring monthly review of forecast movement, changing assumptions, risks and opportunities.
Best for:Businesses that want continued forecast visibility and independent challenge without building an internal analytics resource.
Typical progression
£495 Health Check£1,500 Data Review£3,500 Forecast Pack£750/month Ongoing Advisory
Detailed package information is available on the services page and the dedicated Health Check page.
Xenon combines senior B2B commercial experience with structured analysis.
The work is grounded in 25 years of responsibility for growth, customers, forecasting, strategy and Board-level performance, including helping grow a manufacturing business from launch to £17m revenue.
Analysis is used where it adds value — including segmentation, correlation, regression and backtesting — with assumptions and limitations made clear.
25 years
Senior B2B commercial leadership
£17m
Helped grow a manufacturing business from launch
Experience + evidence
Commercial judgement supported by structured analysis
If you already hold commercial data but are not confident it is helping you forecast future revenue, the £495 Commercial Predictability Health Check is a practical place to start.
Your data will be treated confidentially. The initial discussion is exploratory and does not create an obligation to proceed.